DAPT Calculator
Estimate the recommended duration of dual antiplatelet therapy after coronary stent placement or acute coronary syndrome.
What Is the DAPT Calculator?
The DAPT (Dual Antiplatelet Therapy) Calculator estimates the recommended duration of dual antiplatelet therapy following coronary stent placement or an acute coronary syndrome (ACS). It uses clinical and procedural variables to help clinicians weigh the trade-off between ischemic risk reduction and bleeding risk when deciding between short-term (e.g., 3–6 months) and extended (e.g., 12–30 months) DAPT regimens.
How the DAPT Score Is Calculated
The calculator applies the validated DAPT Study scoring system, which assigns points based on patient and procedural characteristics. The total score stratifies patients into two categories:
- Score ≥ 2 — Longer DAPT (≥ 12 months) is associated with a greater reduction in ischemic events relative to bleeding risk.
- Score < 2 — Shorter DAPT (≤ 12 months) is favored because the bleeding risk outweighs the ischemic benefit.
The scoring considers factors such as age, diabetes status, smoking history, prior PCI or MI, heart failure or LVEF < 30%, vein graft stent placement, and stent diameter.
How to Use the DAPT Calculator
- Enter the patient's age and select relevant clinical history items (diabetes, smoking, prior MI or PCI, heart failure).
- Indicate procedural details: whether a vein graft was stented and the smallest stent diameter used.
- Review the calculated DAPT score and the corresponding recommendation for therapy duration.
The tool is intended for use at the time of decision-making, typically 12 months after stent placement or ACS, when the choice to continue or stop DAPT is being evaluated.
Interpreting the Results
The output provides a numeric DAPT score and a categorical recommendation. A score of 2 or higher suggests that continuing DAPT beyond 12 months may reduce stent thrombosis and major adverse cardiovascular events, though with an increased risk of moderate-to-severe bleeding. A score below 2 indicates that the bleeding risk likely outweighs the ischemic benefit, and stopping DAPT at 12 months is generally appropriate.
The calculator does not replace clinical judgment. Individual patient factors such as bleeding history, concurrent anticoagulation, and patient preference must be incorporated into the final decision.
Common Clinical Considerations
- Bleeding risk assessment: The DAPT score is one component. A separate bleeding risk assessment (e.g., PRECISE-DAPT) may provide additional context.
- Stent type: Newer-generation drug-eluting stents have lower thrombosis rates, which may influence the risk-benefit balance.
- Concurrent anticoagulation: Patients requiring triple therapy (DAPT plus an oral anticoagulant) require individualized management that extends beyond the DAPT score.
Limitations
- The DAPT score was derived from a specific trial population and may not generalize to all patient subgroups.
- It does not account for all bleeding risk factors, such as renal impairment or prior bleeding events.
- The score is validated for decision-making at 12 months post-procedure, not for initial DAPT selection or for use at other time points.
Practical Use Cases
- Cardiology clinic follow-up at 12 months post-stent placement.
- Shared decision-making discussions with patients about continuing or stopping DAPT.
- Structured documentation of the rationale for DAPT duration in the medical record.
FAQ
What does the DAPT score actually predict?
The DAPT score predicts the net clinical benefit of continuing dual antiplatelet therapy beyond 12 months after coronary stent placement. It estimates the reduction in ischemic events (stent thrombosis, MI, stroke) relative to the increase in moderate-to-severe bleeding events.
Can the DAPT calculator be used for patients on anticoagulation?
The DAPT score was not validated in patients receiving concurrent oral anticoagulation. In such cases, the risk-benefit assessment must account for the additional bleeding risk from anticoagulant therapy, and the score should be interpreted with caution.
Is the DAPT score the same as the PRECISE-DAPT score?
No. The DAPT score is used at 12 months post-procedure to decide whether to continue therapy. The PRECISE-DAPT score is used at the time of stent placement to predict bleeding risk during the first year of DAPT. They serve different clinical decision points.
What if the patient has a history of bleeding?
The DAPT score does not directly incorporate prior bleeding events. Clinicians should consider bleeding history separately and may opt for shorter DAPT duration even if the score suggests extended therapy, especially if the prior bleeding was significant or occurred on antiplatelet therapy.